"I hope this will be an opportunity to leap forward as a global bio powerhouse."
Oh Yu-kyung, head of the Korea Food and Drug Administration, made this statement on August 26 at the Grand InterContinental Seoul Parnas in Gangnam, where the '2026 Global Bio Conference (GBC)' is taking place over three days. She added, "The bio industry is a field where innovative technologies are constantly emerging and is growing as a future growth engine. I hope this event accelerates the pace of bio innovation."
Now in its 12th year, this year's conference is themed 'A Great Leap for Bio: Accelerating Innovation' and has attracted around 5,000 participants, including global regulatory authorities and stakeholders from the pharmaceutical and biotech sectors. The event aims to bring together global leaders to explore regulations related to artificial intelligence (AI) and advanced biopharmaceuticals, as well as directions for international cooperation.
During the opening ceremony, President Lee Jae-myung delivered a congratulatory message via video. Additionally, keynote speeches were given by Lee Sang-yup, a distinguished professor at KAIST, and Jeremy Farrar, Deputy Director-General of the World Health Organization (WHO), among other global figures in the pharmaceutical and biotech industries.
Notably, the newly established 'GBC Special: K-Bio Innovation Leaders Talk' garnered attention this year. Business leaders who have driven the domestic biotech industry shared their experiences of success and challenges in commercialization, as well as strategies for entering the global market. Founders from Alteogen, ABL Bio, Curexcell, and Organoid Science took the stage, with former Korea Drug Evaluation Institute head Park Yoon-joo serving as the moderator.
On August 27 and 28, forums on vaccines, recombinant pharmaceuticals, and the biopharmaceutical supply chain will be held. The vaccine forum will share trends in vaccine evaluation based on regulatory science, while the recombinant pharmaceuticals forum will examine advancements in antibody treatment development technologies using AI and regulatory trends. The biopharmaceutical supply chain forum will discuss strategies to overcome vulnerabilities in supply chains that may arise from crises such as pandemics, geopolitical conflicts, and raw material supply instability.
Oh Yu-kyung, head of the Korea Food and Drug Administration, made this statement on August 26 at the Grand InterContinental Seoul Parnas in Gangnam, where the '2026 Global Bio Conference (GBC)' is taking place over three days. She added, "The bio industry is a field where innovative technologies are constantly emerging and is growing as a future growth engine. I hope this event accelerates the pace of bio innovation."
Now in its 12th year, this year's conference is themed 'A Great Leap for Bio: Accelerating Innovation' and has attracted around 5,000 participants, including global regulatory authorities and stakeholders from the pharmaceutical and biotech sectors. The event aims to bring together global leaders to explore regulations related to artificial intelligence (AI) and advanced biopharmaceuticals, as well as directions for international cooperation.
During the opening ceremony, President Lee Jae-myung delivered a congratulatory message via video. Additionally, keynote speeches were given by Lee Sang-yup, a distinguished professor at KAIST, and Jeremy Farrar, Deputy Director-General of the World Health Organization (WHO), among other global figures in the pharmaceutical and biotech industries.
Notably, the newly established 'GBC Special: K-Bio Innovation Leaders Talk' garnered attention this year. Business leaders who have driven the domestic biotech industry shared their experiences of success and challenges in commercialization, as well as strategies for entering the global market. Founders from Alteogen, ABL Bio, Curexcell, and Organoid Science took the stage, with former Korea Drug Evaluation Institute head Park Yoon-joo serving as the moderator.
On August 27 and 28, forums on vaccines, recombinant pharmaceuticals, and the biopharmaceutical supply chain will be held. The vaccine forum will share trends in vaccine evaluation based on regulatory science, while the recombinant pharmaceuticals forum will examine advancements in antibody treatment development technologies using AI and regulatory trends. The biopharmaceutical supply chain forum will discuss strategies to overcome vulnerabilities in supply chains that may arise from crises such as pandemics, geopolitical conflicts, and raw material supply instability.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.